Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain RARE message board posts where the ticker symbol RARE has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest RARE SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-061480 Size: 5 KB
2018-12-07
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001564590-18-029557 (34 Act)  Size: 522 KB
2018-11-14 001-36276
181183525
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-057820 Size: 5 KB
2018-11-08
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-18-026944 (34 Act)  Size: 5 MB
2018-11-06 001-36276
181161035
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001564590-18-026840 (34 Act)  Size: 700 KB
2018-11-05 001-36276
181160031
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-056702 Size: 7 KB
2018-10-31
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-054531 Size: 17 KB
2018-10-09
3/A  Documents [Amend] Initial statement of beneficial ownership of securities
Acc-no: 0001209191-18-054529 Size: 5 KB
2018-10-09
4/A  Documents [Amend] Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-054521 Size: 9 KB
2018-10-09
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-054519 Size: 7 KB
2018-10-09
More RARE SEC Filings


Related news from
Thu, 13 Dec 2018
13:02:30 +0000
See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RARE
Thu, 13 Dec 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Ultragenyx Pharmaceutical
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
Thu, 06 Dec 2018
13:30:00 +0000
Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X–linked Hypophosphatemia (XLH) in Adults and Children
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that Crysvita™ (burosumab injection) has been approved by Health Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older. The product is expected to be available for prescription to Canadian patients in early 2019.
Wed, 05 Dec 2018
14:30:02 +0000
Ultragenyx (RARE) Down 7.2% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wed, 21 Nov 2018
06:52:01 +0000
Edited Transcript of RARE earnings conference call or presentation 5-Nov-18 10:00pm GMT
Q3 2018 Ultragenyx Pharmaceutical Inc Earnings Call
Wed, 14 Nov 2018
13:30:00 +0000
Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019
NOVATO, Calif., Nov. 14, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and.
Fri, 09 Nov 2018
12:35:00 +0000
Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Tue, 06 Nov 2018
21:31:09 +0000
Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3
Ultragenyx (RARE) submitts regulatory filings in Canada, Brazil and Colombia for Crysvita for the treatment of XLH.
Tue, 06 Nov 2018
05:30:23 +0000
Amazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending
Although November 6 is very important to the stock market because it’s election day in the United States, traders are also paying attention to several equities that are trending for various reasons. Without further elaboration, let’s dive in and see why the spotlight is shining on Amazon.com Inc. (NASDAQ:AMZN), The Kraft Heinz Company (NASDAQ:KHC),  Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), PTC […]
Mon, 05 Nov 2018
22:20:10 +0000
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of 10.31% and 5.01%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Mon, 05 Nov 2018
21:15:42 +0000
Ultragenyx: 3Q Earnings Snapshot
On a per-share basis, the Novato, California-based company said it had a loss of $1.74. The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research ...
Mon, 05 Nov 2018
21:05:00 +0000
Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update
NOVATO, Calif., Nov. 05, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and.
Fri, 02 Nov 2018
15:41:03 +0000
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Wed, 31 Oct 2018
18:08:06 +0000
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Tue, 30 Oct 2018
12:30:00 +0000
Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, November 5, 2018 at 5pm ET to discuss third quarter 2018 financial results and provide a corporate update. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.
Fri, 26 Oct 2018
12:00:00 +0000
Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced its Phase 3 study of UX007 in patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) experiencing disabling paroxysmal movement disorders did not achieve its primary endpoint of demonstrating a statistically significant reduction in the frequency of paroxysmal movement events with UX007 treatment compared to placebo, and did not demonstrate a meaningful difference between treatment groups. The study also did not meet its key secondary endpoints.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is comprised of a large and growing, diverse, knowledgeable group of investors. The attribute you should appreciate that this wonderful group makes available to you as an incoming member is Generosity. Research, firsthand sector sophistication, source references and sometimes remarkably insightful analyses are given freely by the members so you may do your own due dilligence in making informed investment decisions." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards